Covid vaccines - thread banned users in First Post

One was the lower bound value for a 94.7% efficacy for those over 65 with a 95% CI, the other was the effectiveness against severe disease.

I did it from memory as the graph was on the previous page and then literally said feel free to argue about the .3 if I have it wrong if you want to, I even highlighted the number for you directly (unless you feel the 0.4 difference is in any way significant, or want to show your misunderstandings of confidence intervals again).

And you've gone and done that:

Note the 66.3 (the decimal .3 might be off, you can argue if it isn't .3) in the table

Here's a genuine question that I've stated the answer to multiple times:

Why did I include the sentence you were hiding, the entire paragraph and then the table with data relating to the paragraph (but not the severity data which was supplied in a separate table above)?

Given that I have stated it clearly multiple times, you should be able to provide a coherent answer here that isn't the babblings of a raving lunatic.

3.3. Uncertainties and limitations about favourable effects Based on the available limited data, no reliable conclusion on the efficacy of the vaccine against severe COVID-19 can be drawn from 7 days after the second dose (secondary endpoint). The estimated efficacy against severe COVID-19 occurring at least 7 days after dose 2 was 66.4%, with a large and negative lower bound CI (95% CI: -124.8%; 96.3%). Only a limited number of events occurred at the cut-off date of analysis (1 and 4 cases in the vaccine and placebo groups respectively). The posterior probability for the true vaccine efficacy ≥ 30% (74.29%) did not meet the pre-specified success criterion. Consequently, the efficacy against the severe disease across subgroups, notably certain populations at high-risk of severe COVID-19 cannot be estimated (elderly and subjects with comorbidities). Efficacy against asymptomatic infection is not available but, notwithstanding all the limitations, will be assessed through seroconversion of N-binding antibodies in BNT162b2 and placebo recipients who did not experience COVID-19. The pivotal study was not designed to assess the effect of the vaccine against transmission of SARSCoV-2 from subjects who would be infected after vaccination. The efficacy of the vaccine in preventing SARS-CoV-2 shedding and transmission, in particular from individuals with asymptomatic infection, can only be evaluated post-authorisation in epidemiological or specific clinical studies. Duration of protection has currently been followed up for approximately 100 days after dose 1. Data on longer term protection are anticipated to the extent that the ongoing phase 3 study can continue as planned with a placebo group. The assessment of efficacy over a period of at least 6 months is expected to determine the need and the appropriate time of a booster dose. There seems to be at least a partial onset of protection after the first dose, but this remains unconfirmed at this stage. There are very limited or no data in immunocompromised subjects and in pregnant women. Efficacy in subjects aged 16-17 years is extrapolated from young adults as no cases of disease were reported in this small group at this stage. Available data do not suffice to establish efficacy in subjects seropositive for SARS-CoV-2 at baseline, and subjects with a known history of COVID-19. However, efficacy is anticipated in this group, to the extent that they are not naturally protected against re-infection, which is presently incompletely characterised.

And just to show the data table (95% CI would mean there's a 1/20 chance that if the trial was repeated it wouldn't show substantially different numbers, with a 95% chance of those numbers varying between 90.0 and 97.9), again, this CI was included in the day 1 data for all vaccines, which is what the real world data later improved upon):

Based on the available limited data, no reliable conclusion on the efficacy of the vaccine against severe COVID-19 can be drawn from 7 days after the second dose (secondary endpoint).